Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04626128 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD
A Phase 1 study, sponsored by Clearside Biomedical.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT04626128 is a Phase 1 study that has completed, run by Clearside Biomedical. The registered enrollment target is 27 participants.
The verdict
NCT04626128, a Phase 1 study, has completed, sponsored by Clearside Biomedical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of suprachoroidally administered CLS-AX following intravitreal anti-VEGF therapy in subjects with neovascular age-related macular degeneration (AMD)
Interventions
- DRUG CLS-AX
- DRUG Anti-VEGF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2022-10-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04626128
The ClinicalTrials.gov registry entry for NCT04626128 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clearside Biomedical, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CLS-AX is the first listed.
NCT04626128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04626128 about?
NCT04626128 is a clinical study titled "Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD". To evaluate the safety and tolerability of suprachoroidally administered CLS-AX following intravitreal anti-VEGF therapy in subjects with neovascular age-related macular degeneration (AMD)
What is the current status of trial NCT04626128?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2020-12-15. Estimated completion is 2022-10-13.
What interventions are being tested in trial NCT04626128?
The interventions under investigation include: CLS-AX (DRUG), Anti-VEGF (DRUG).
Who is sponsoring clinical trial NCT04626128?
This trial is sponsored by Clearside Biomedical, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.